United States securities and exchange commission logo





                          March 20, 2024

       Stephen Stamp
       Chief Executive Officer
       Biodexa Pharmaceuticals Plc
       Caspian Point
       Caspian Way
       Cardiff, CF10 4DQ, United Kingdom

                                                        Re: Biodexa
Pharmaceuticals Plc
                                                            Registration
Statement on Form F-1
                                                            Filed March 18,
2024
                                                            File No. 333-278040

       Dear Stephen Stamp:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Chris
Edwards at 202-551-6761 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Donald J. Puglisi